Why the study?
It was hypothesized that levosimendan could attenuate myocardial injury compared with milrinone in infants undergoing corrective cardiac surgery.
Does levosimendan reduce myocardial injury biomarkers compared to milrinone in infants undergoing corrective cardiac surgery with cardiopulmonary bypass?
Does levosimendan reduce myocardial injury biomarkers compared to milrinone in infants undergoing corrective cardiac surgery with cardiopulmonary bypass?
Levosimendan does not attenuate myocardial injury or improve ventricular function biomarkers compared to milrinone in infants undergoing corrective cardiac surgery.
No biomarker differences observed; leaves open whether levosimendan offers benefit over milrinone in infant cardiac surgery.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Thorlacius et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: